Review Article

Total Page:16

File Type:pdf, Size:1020Kb

Review Article Headache ISSN 0017-8748 C 2006 by American Headache Society doi: 10.1111/j.1526-4610.2006.00370.x Published by Blackwell Publishing Review Article Ovarian Hormones and Migraine Headache: Understanding Mechanisms and Pathogenesis—Part 2 Vincent T. Martin, MD; Michael Behbehani, PhD Migraine headache is strongly influenced by reproductive events that occur throughout the lifespan of women. Each of these reproductive events has a different “hormonal milieu,” which might modulate the clinical course of migraine headache. Estrogen and progesterone can be preventative or provocative for migraine headache un- der different circumstances depending on their absolute serum levels, constancy of exposure, and types of estro- gen/progesterone derivatives. Attacks of migraine with and without aura respond differently to changes in ovarian hormones. Clearly a greater knowledge of ovarian hormones and their effect on migraine is essential to a greater understanding of the mechanisms and pathogenesis of migraine headache. Key words: menstrual migraine, migraine headache, estrogen, progesterone, menstrual cycle, menarche, pregnancy, menopause, lactation Abbreviations: GnRH gonadotropin-releasing hormone, HRT hormone replacement therapy, OCPs oral contra- ceptives, PROGINS progesterone receptor allele, CVA cerebrovascular accident, CNS central nervous system, CI confidence intervals, HR hazard ratio, MAO-B monoamine oxidase-B, NMDA N-methyl-d-aspartate, AUC area-under-the-curve, TNC trigeminal nucleus caudalis, GABA gamma aminobutyric acid (Headache 2006;46:365-386) During part 1 of this series, we reviewed the ge- pathogenesis of migraine headache. Numerous clini- nomic and nongenomic effects of ovarian hormones cal studies also exist to provide clues to how ovarian on the central nervous system as well as the current hormones might modulate migraine headaches. Mi- basic science studies linking them to the pathogene- graine headaches are likely influenced by the different sis of migraine headache. These studies clearly indi- “hormonal milieus” encountered during reproductive cate that ovarian hormones can alter neurotransmit- life events that begin during menarche and continue ter systems theorized to play an important role in the through menopause. The purpose of this manuscript will be to review existing clinical studies examining From the Department of Internal Medicine, University of the course of migraine headache during reproductive Cincinnati College of Medicine Cincinnati, Ohio (Dr. Martin); life events (eg, menarche, menstrual cycles, pregnancy, and Department of Molecular and Cellular Physiology, Uni- lactation, and menopause) as well as after administra- versity of Cincinnati College of Medicine, Cincinnati, Ohio (Dr. Behbehani) tion of exogenous hormones (eg, oral contraceptives [OCPs] and hormone replacement therapy [HRT]). Address all correspondence to Dr. Vincent T. Martin, Depart- ment of Internal Medicine, University of Cincinnati College We will also define the specific serum levels of ovar- of Medicine, 231 Albert Sabin Way, ML 6603, Cincinnati, OH ian hormones encountered during the different repro- 45267-0535, USA. ductive life events and postulate mechanisms through Accepted for publication December 16, 2005. which they might affect migraine headache. 365 366 March 2006 MENARCHE ENDOCRINOLOGY OF THE MENSTRUAL Menarche refers to the onset of menstruation dur- CYCLE ing puberty. The typical age range of menarche is 9.1 The menstrual cycle is divided into follicular and to 17.7 years with a median age of 12.8 years within luteal phases. The follicular phase includes all days American girls.1,2 The initial menstrual cycles are of- from the first day of menstrual bleeding to the day ten anovulatory and may remain so for the first 12 to before ovulation and the luteal phase includes all days 18 months after the onset of menarche. Serum estra- from the first day of ovulation to the last day before diol levels range from 10 to 156 pg/mL during puberty the next menstrual period. The follicular and luteal prior to the onset of ovulatory menstrual cycles; serum phases can further be subdivided into early, mid, and levels of estrogen and progesterone similar to those late time intervals. Serum estradiol levels typically are encountered during the adult menstrual cycle may low during the early to mid-follicular phases (eg, 25 not be reached until several years after the onset of to 50 pg/mL range), peak during the late follicular menarche.3 and early luteal phase (eg, 100 to 400 pg/mL range), The prevalence of migraine is similar in preadoles- plateau during the mid-luteal phase (200 to 300 pg/mL cent boys and girls, but diverges at the time of menar- range), and fall precipitously to levels of 25 to 50 pg/mL che.4 After menarche, the prevalence is 2 to 3 times just prior to menstruation. Serum progesterone lev- higher in girls than in boys and remains so throughout els are extremely low during the follicular phase (<1 most of the reproductive years. The age of onset of ng/mL range), peak during the mid-luteal phase at lev- migraine tends to differ between girls experiencing at- els ranging from 6 to 10 ng/mL, and then fall precipi- tacks of migraine with and without aura. Stewart et al5 tously to levels <2 ng/mL during the late luteal phase reported the peak incidence of migraine was 12 to 13 (Figure 1). years of age for girls experiencing migraine with aura (MWA) (14.1 cases per 1000 person years) and 14 to MENSTRUAL MIGRAINE 17 years of age for those experiencing migraine with- Menstrual migraine has recently been defined out aura (MWoA) (18.9 cases per 1000 person years). by the International Headache Society in the ap- Thus MWoA most commonly begins after the onset of pendix of their diagnostic criteria for headache and menarche, while MWA usually begins shortly before has been divided into 2 subcategories: “menstrually or at the time of menarche. Since ovulation and regular related MWoA” and “pure menstrual MWoA.” The menstrual cycles may not develop for 1 to 2 years after criteria for “menstrually related MWoA” include: menarche, it is likely that the onset of MWoA is asso- ciated with the establishment of the female menstrual cycle. Follicular Luteal Early Mid Late Early Mid Late 500 12 400 10 8 MENSTRUAL CYCLE 300 6 Migraine headaches could theoretically be influ- 200 4 enced by changes in ovarian hormones that occur Level (ng/ml)Level Level (pg/ml) Level 100 Serum Estradiol Estradiol Serum 2 throughout the female menstrual cycle. Knowledge 0 0 Serum Progesterone of the different “hormonal milieus” encountered dur- 1 4 7 10131619222528 ing different phases of the menstrual cycle is essen- Days of Menstrual Cycle tial to an understanding of the effects of ovarian hor- mones on migraine headache. Therefore, in the next Fig 1.—Changes in serum estrogen and progesterone levels dur- several sections, we will review the endocrinology of ing a native menstrual cycle. Day 1 is the first day of menses and the menstrual cycle as well as the potential mecha- day 27 is the last day before the next menstrual period. The fol- licular phase includes all days prior to ovulation and the luteal nisms through which ovarian hormones could modu- phase includes all days after ovulation. The follicular and luteal late menstrual and nonmenstrual migraine headaches. phases can be divided into early, mid, and late time periods. Headache 367 (1) predictable migraine attacks occurring during the difference between the attack characteristics of men- , perimenstrual time period (2 days before to 3 days af- strual and nonmenstrual migraine.14 15 Studies within ter the onset of menstruation), (2) migraines also oc- subspecialty-based clinics, however, suggest that men- cur at other times of the month, and (3) the association strual migraine is more severe, disabling, and as- with menses must be confirmed in 2/3 menstrual cycles. sociated with greater abortive medication use than “Pure menstrual MWoA” is similar to the above crite- nonmenstrually related migraine.16-18 The discrepan- ria, except that migraine headaches are strictly limited cies between specialty- and population-based studies to the perimenstrual time period and do not occur at most likely can be explained by their selection of pa- other times of the menstrual cycle. For the sake of this tients. Subspecialty-based studies may have included a review, we will refer to both types of migraine as “men- greater percentage of “hormonally sensitive” patients strual migraine.” than population-based studies, thus allowing a greater Epidemiology.—The overall prevalence of men- chance of identifying differences between menstrually strual migraine in the general population is approx- related and nonmenstrually related attacks. imately 3%, but it is much higher within populations Effect on MWoA.—Interestingly only attacks of of migraineurs6; 35% to 51% of female migraineurs MWoA occur during the perimenstrual time period. have “menstrually related MWoA,” while 7% to 19% Stewart et al15 reported that attacks of MWoA were have “pure menstrual MWoA”7-13 (Table 1). 2.04 times more likely during the first 2 days of men- Attack Characteristics.—Population-based studies struation, while attacks of MWA occurred with equal of nonselected female migraineurs demonstrate little frequency throughout the menstrual cycle. Johannes Table 1.—Prevalence of Menstrual Migraine in Female Migraineurs∗ Study Method of Ascertainment Prevalence Prevalence Author/Year (n) Population of Menstrual Migraine of PMM of MRM MacGregor/1990
Recommended publications
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • 761089Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 761089Orig1s000 CLINICAL / STATISTICAL REVIEW(S) Safety Team Leader Review BLA 761089 Ajovy (Fremanezumab) Safety Team Leader Review Date September 14, 2018 From Sally Usdin Yasuda Subject Safety Team Leader Review NDA/BLA # BLA 761089 Supplement# Applicant Teva Pharmaceuticals USA, Inc. Date of Submission October 16, 2017 PDUFA Goal Date June 16, 2018 Proprietary Name / Non- Ajovy/Fremanezumab Proprietary Name Dosage form(s) / Strength(s) Solution for subcutaneous injection, 225 mg/1.5 ml Applicant Proposed Preventive treatment of migraine in adult patients Indication(s)/Population(s) There do not appear to be safety concerns that would preclude approval. If efficacy is demonstrated and the Recommendation on benefits of fremanezumab for prevention of migraine Regulatory Action outweigh the risks, then I recommend that approval include appropriate labeling language addressing any adverse reactions of concern. Recommended Indication(s)/Population(s) (if applicable) 1 Reference ID: 4320823 Safety Team Leader Review BLA 761089 Ajovy (Fremanezumab) 1. Background This memorandum summarizes the primary concerns from the safety review conducted by Dr. Lourdes Villalba of the fremanezumab BLA 761089 and provides my conclusions and recommendations regarding the safety findings and management of the risks. I also discuss the consultant reviews from Dr. Wiley Chambers (Division of Transplant and Ophthalmology Products). The product information and the applicant’s proposals Fremanezumab is a humanized monoclonal IgG2 antibody that, according to the Sponsor, is a calcitonin gene-related peptide (CGRP) binder that blocks both CGRP isoforms (α- and β) so that CGRP is blocked from binding to the CGRP receptor.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • E Cacy and Safety of CGRP Monoclonal
    Ecacy and Safety of CGRP Monoclonal Antibodies for the Prevention of Migraine Compared with Placebo: A Systematic Review and Meta-Analysis Xiaojing Yi Hunan Normal University Yun Chen Hunan Normal University Kun Chen Hunan Normal University Mo Liu Hunan Normal University Jiale Yi Hunan Normal University Xiongwei Hu Hunan Normal University Guibin Wang ( [email protected] ) Research article Keywords: Migraine, Calcitonin gene-related peptide, Monoclonal antibodies, Preventive treatment, Meta-analysis Posted Date: July 14th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-39329/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/20 Abstract Background: Calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) are a novel class of drugs for migraine that includes erenumab, fremanezumab, galcanezumab and eptinezumab. In clinical trials, CGRP mAbs have been reported to show good ecacy in the prevention of episodic migraines or chronic migraines. Our aim was to evaluate the ecacy and safety of CGRP monoclonal antibodies in this study. Methods: We systematically searched for randomized controlled trials in the PubMed, Embase, ClinicalTrials.gov, and Cochrane Library databases. The primary outcome was overall mean change from baseline to end of treatment in the number of monthly migraine headache days (MMHDs). The secondary outcomes included 50% response rate, in the number of monthly headache days (MHDs), in the number of monthly headache hours (MHHs), and in the number of monthly acute migraine-specic medication days (MSMDs). The safety outcomes were evaluated in terms of reported adverse events. Results: Eighteen studies including 11,099 patients were included in the meta-analysis.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Treating Migraines: It's Different for Kids
    ® Priority Updates from the Research Literature PURLs from the Family Physicians Inquiries Network Matthew Hawks, MD; Anne Mounsey, MD Nellis AFB Family Medicine Treating migraines: Residency, Las Vegas, Nev (Dr. Hawks); Department of Family Medicine, The It’s different for kids University of North Carolina, Chapel Hill (Dr. Mounsey) Certain medications used for migraine prevention in DEPUTY EDITOR adults do not perform the same way in children and Shailendra Prasad, MBBS, MPH adolescents and can actually cause harm. Department of Family Medicine and Community Health, University of Minnesota, Minneapolis PRACTICE CHANGER Drug Administration (FDA) has not approved Do not prescribe amitriptyline or topiramate any medications for preventing migraines as preventive therapy for migraine in chil- in children younger than 12 years of age. dren; both drugs are no better than placebo However, surveys of pediatric headache for this population and are associated with specialists suggest that amitriptyline and increased rates of adverse events.1,2 topiramate are among the most commonly prescribed medications for childhood mi- STRENGTH OF RECOMMENDATION graine prophylaxis.3,4 A: Based on a single double-blind random- There is low-quality evidence from indi- ized control trial (RCT) and supported by a vidual randomized controlled trials (RCTs) meta-analysis of 4 RCTs. about the effectiveness of topiramate. A me- 1. Powers SW, Coffey CS, Chamberlin LA, et al; for the CHAMP Inves- ta-analysis by El-Chammas and colleagues tigators. Trial of amitriptyline, topiramate, and placebo for pediatric migraine. N Engl J Med. 2017;376:115-124. included 3 RCTs comparing topiramate to 2. Le K, Yu D, Wang J, et al.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 De Juan Et Al
    US 20110159073A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 de Juan et al. (43) Pub. Date: Jun. 30, 2011 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA A6F 2/00 (2006.01) (US); Signe E. Varner, Los (52) U.S. Cl. ........................................................ 424/427 Angeles, CA (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Featured is a method for instilling one or more bioactive (21) Appl. No.: 12/981,038 agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising con (22) Filed: Dec. 29, 2010 currently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a Sustained release Related U.S. Application Data delivery device comprising one or more bioactive agents in a (63) Continuation of application No. 1 1/175,850, filed on posterior region of the eye so that it delivers the one or more Jul. 5, 2005, now abandoned. bioactive agents into the vitreous humor of the eye; (B) instill ing (e.g., injecting or implanting) one or more bioactive (60) Provisional application No. 60/585,236, filed on Jul. 2, agents Subretinally; and (C) instilling (e.g., injecting or deliv 2004, provisional application No. 60/669,701, filed on ering by ocular iontophoresis) one or more bioactive agents Apr. 8, 2005. into the vitreous humor of the eye. Patent Application Publication Jun. 30, 2011 Sheet 1 of 22 US 2011/O159073 A1 Patent Application Publication Jun.
    [Show full text]
  • United States Patent 19 11 Patent Number: 5,446,070 Mantelle (45) Date of Patent: "Aug
    USOO544607OA United States Patent 19 11 Patent Number: 5,446,070 Mantelle (45) Date of Patent: "Aug. 29, 1995 54 COMPOST ONS AND METHODS FOR 4,659,714 4/1987 Watt-Smith ......................... 514/260 TOPCAL ADMNSTRATION OF 4,675,009 6/1987 Hymes .......... ... 604/304 PHARMACEUTICALLY ACTIVE AGENTS 4,695,465 9/1987 Kigasawa .............................. 424/19 4,748,022 5/1988 Busciglio. ... 424/195 75 Inventor: Juan A. Mantelle, Miami, Fla. 4,765,983 8/1988 Takayanagi. ... 424/434 4,789,667 12/1988 Makino ............ ... 514/16 73) Assignee: Nover Pharmaceuticals, Inc., Miami, 4,867,970 9/1989 Newsham et al. ... 424/435 Fla. 4,888,354 12/1989 Chang .............. ... 514/424 4,894,232 1/1990 Reul ............. ... 424/439 * Notice: The portion of the term of this patent 4,900,552 2/1990 Sanvordeker .... ... 424/422 subsequent to Aug. 10, 2010 has been 4,900,554 2/1990 Yanagibashi. ... 424/448 disclaimed. 4,937,078 6/1990 Mezei........... ... 424/450 Appl. No.: 112,330 4,940,587 7/1990 Jenkins ..... ... 424/480 21 4,981,875 l/1991 Leusner ... ... 514/774 22 Filed: Aug. 27, 1993 5,023,082 6/1991 Friedman . ... 424/426 5,234,957 8/1993 Mantelle ........................... 514/772.6 Related U.S. Application Data FOREIGN PATENT DOCUMENTS 63 Continuation-in-part of PCT/US92/01730, Feb. 27, 0002425 6/1979 European Pat. Off. 1992, which is a continuation-in-part of Ser. No. 0139127 5/1985 European Pat. Off. 813,196, Dec. 23, 1991, Pat. No. 5,234,957, which is a 0159168 10/1985 European Pat.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]